	BIEO	IOB2
High-risk	O	O
human	B-virus	B-virus
papillomavirus	E-virus	I-virus
(	O	O
HPV	B-virus	B-virus
)	O	O
recognised	O	O
principal	O	O
cause	O	O
increasing	O	O
incidence	O	O
rates	O	O
oropharyngeal	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
(	O	O
OPSCC	O	O
)	O	O
parts	O	O
world	O	O
.	O	O
		
The	O	O
primary	O	O
risk	O	O
factor	O	O
developing	O	O
HPV-related	B-virus	B-virus
OPSCC	O	O
oral	O	O
HPV-infection	B-virus	B-virus
majority	O	O
oral	O	O
HPV-infections	B-virus	B-virus
acquired	O	O
oral	O	O
sex	O	O
.	O	O
		
Progression	O	O
OPSCC	O	O
includes	O	O
persistent	O	O
infection	O	O
evasion	O	O
immune	O	O
response	O	O
microenvironment	O	O
,	O	O
activation	O	O
viral	O	O
early	O	O
genes	O	O
(	O	O
E6	O	O
,	O	O
E7	O	O
)	O	O
basal	O	O
epithelial	O	O
cells	O	O
,	O	O
deregulation	O	O
cell	O	O
cycle	O	O
accumulation	O	O
chromosomal	O	O
instability	O	O
.	O	O
		
Patients	O	O
affected	O	O
HPV-related	B-virus	B-virus
OPSCC	O	O
tend	O	O
younger	O	O
better	O	O
outcomes	O	O
.	O	O
		
This	O	O
observation	O	O
lead	O	O
current	O	O
research	O	O
evaluate	O	O
treatment	O	O
de-escalation	O	O
options	O	O
reduce	O	O
long-term	O	O
associated	O	O
morbidity	O	O
.	O	O
		
Moreover	O	O
,	O	O
different	O	O
molecular	O	O
profile	O	O
HPV-related	B-virus	B-virus
OPSCC	O	O
described	O	O
,	O	O
opening	O	O
new	O	O
options	O	O
targeted	O	O
therapy	O	O
immunotherapy	O	O
approaches	O	O
.	O	O
		
This	O	O
paper	O	O
comprehensively	O	O
reviews	O	O
accumulated	O	O
knowledge	O	O
regarding	O	O
role	O	O
HPV	B-virus	B-virus
OPSCC	O	O
spanning	O	O
infection	O	O
cancer	O	O
development	O	O
,	O	O
including	O	O
clinical	O	O
diagnosis	O	O
,	O	O
management	O	O
preventive	O	O
strategies	O	O
.	O	O
